Helicore Biopharma develops first-in-class GIP antagonists, including HCR-188, a clinical-stage monoclonal antibody that binds circulating GIP. The company's portfolio includes GIP antibody conjugates and combinations with GLP-1 designed to address specific obesity subpopulations. Helicore leverages human genetics, proprietary preclinical data, and third-party clinical studies to design target product profiles and link GIP antagonism to potential preferential fat loss and restored leptin sensitivity. Preclinical studies of HCR-188 in combination with GLP-1 suggest preferential loss of fat over lean mass and additional cardiometabolic benefits. Helicore emerged from stealth with $65 million in Series A financing to advance its clinical program. R&D is supported by protein engineering capabilities at Ridgeline, Versant’s discovery engine based in Switzerland, and the company plans rapid progress advancing HCR-188 and its antibody conjugate portfolio in 2025.

Total raised

$65M

Funding rounds

1

Latest round

Series A

Latest activity

Feb 2025